Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence

Clinical Transplantation

Volumn 29, Issue 7, 2015, Pages 606-611

  Mujtaba, Muhammad A ^a   Sharfuddin, Asif A ^b   Book, Benita L ^b   Goggins, William C ^b   Khalil, Ali A ^b   Mishler, Dennis P ^b   Fridell, Johnathan A ^b   Yaqub, Muhammad S ^b   Taber, Tim E ^b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti AT1R; Focal segmental glomerulosclerosis; Recurrence; Transplant

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTIBODY; RECEPTOR ANTIBODY; SOLUBLE UROKINASE RECEPTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; AUTOANTIBODY;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; KIDNEY BIOPSY; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; ADVERSE EFFECTS; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; FOLLOW UP; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR;

AUTOANTIBODIES; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RECEPTOR, ANGIOTENSIN, TYPE 1; RECURRENCE; RISK FACTORS;

EID: 84937145935     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12562     Document Type: Article

References (33)

1. D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med 2011: 365: 2398.
2. D'Agati VD, Alster JM, Jennette JC et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol 2013: 8: 399.
3. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004: 43: 368.
4. Weber S, Tonshoff B. Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects. Transplantation 2005: 80(1 Suppl): S128.
5. Cibrik DM, Kaplan B, Campbell DA, Meier-Kriesche HU. Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis. Am J Transplant 2003: 3: 64.
6. Savin VJ, Sharma R, Sharma M et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996: 334: 878.
7. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010: 5: 2115.
8. Gallon L, Leventhal J, Skaro A, Kanwar Y, Alvarado A. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 2012: 366: 1648.
9. Deegens JK, Andresdottir MB, Croockewit S, Wetzels JF. Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int 2004: 17: 151.
10. Artero ML, Sharma R, Savin VJ, Vincenti F. Plasmapheresis reduces proteinuria and serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 1994: 23: 574.
11. Gohh RY, Yango AF, Morrissey PE et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 2005: 5: 2907.
12. Wei C, El Hindi S, Li J et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011: 17: 952.
13. Benigni A, Tomasoni S, Gagliardini E et al. Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 2001: 12: 941.
14. Nakamura T, Obata J, Kimura H et al. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999: 55: 877.
15. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996: 334: 1649.
16. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992: 90: 766.
17. Reinsmoen NL, Lai CH, Mirocha J et al. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation 2014: 97: 595.
18. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006: 20: 953.
19. Suzuki K, Han GD, Miyauchi N et al. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol 2007: 170: 1841.
20. Senggutuvan P, Cameron JS, Hartley RB et al. Recurrence of focal segmental glomerulosclerosis in transplanted kidneys: analysis of incidence and risk factors in 59 allografts. Pediatr Nephrol 1990: 4: 21.
21. Ponticelli C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant 2010: 25: 25.
22. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005: 5: 1179.
23. Abbott KC, Sawyers ES, Oliver JD III et al. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am J Kidney Dis 2001: 37: 366.
24. Bock ME, Price HE, Gallon L, Langman CB. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report. Clin J Am Soc Nephrol 2013: 8: 1304.
25. Meijers B, Maas RJ, Sprangers B et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int 2014: 85: 636.
26. Halleck F, Staeck O, Neumayer HH, Budde K, Khadzhynov D. Supar in transplant patients with FSGS recurrence. Nephrol Dial Transplant 2014: 29: 539.
27. Kelsey R. Transplantation: urine-but not serum-suPAR might predict FSGS recurrence. Nat Rev Nephrol 2013: 9: 432.
28. Alachkar N, Gupta G, Montgomery RA. Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med 2013: 368: 971.
29. Taniguchi M, Rebellato LM, Cai J et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant 2013: 13: 2577.
30. Zhao Y, Wang H, Li X et al. Ang II-AT1R increases cell migration through PI3K/AKT and NF-kappaB pathways in breast cancer. J Cell Physiol 2014: 229: 1855.
31. Yamazaki T, Suzuki J, Shimamoto R et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an angiotensin II receptor blocker. Int Heart J 2007: 48: 715.
32. Thapa L, He CM, Chen HP. Study on the expression of angiotensin II (ANG II) receptor subtype 1 (AT1R) in the placenta of pregnancy-induced hypertension. Placenta 2004: 25: 637.
33. Wallukat G, Homuth V, Fischer T et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999: 103: 945.